Rpts. GENERAL General Schedule (Code GE)

Size: px
Start display at page:

Download "Rpts. GENERAL General Schedule (Code GE)"

Transcription

1 Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease

2 Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Scleroderma oesophagus

3 Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Zollinger-Ellison syndrome

4 Pantoprazole 40mg Name, Restriction, Pantoprazole 40mg enteric tablet, 30 (8007K) Pantoprazole 40mg enteric coated granules, 30 sachets (9423Y) Peptic Ulcer Treatment phase: Clinical criteria: Initial treatment The therapy must be for initial treatment of a peptic ulcer, in a patient testing negative for helicobacter pylori infection OR The patient must have failed treatment with helicobacter pylori eradication therapy Helicobacter pylori eradication therapy should be considered. No increase in the maximum number of repeats may be authorised. Low dose proton pump inhibitors are appropriate step-down therapy from standard dose proton pump inhibitors A low dose proton pump inhibitor includes: lansoprazole 15mg, omeprazole 10mg, pantoprazole 20mg and rabeprazole 10mg steppingup therapy No increase in the maximum quantity or number of repeats may be authorised.

5 Name, Restriction, Pantoprazole 40mg enteric tablet, 30 (8008L) Max. Pantoprazole 40mg enteric coated granules, 30 sachets (9424B) Scleroderma oesophagus Treatment criteria: Must be treated by a gastroenterologist or in consultation with a gastroenterologist Low dose proton pump inhibitors are appropriate step-down therapy from standard dose proton pump inhibitors A low dose proton pump inhibitor includes: lansoprazole 15mg, omeprazole 10mg, pantoprazole 20mg and rabeprazole 10mg No increase in the maximum quantity or number of repeats may be authorised.

6 Name, Restriction, Pantoprazole 40mg enteric tablet, 30 (8008L) Pantoprazole 40mg enteric coated granules, 30 sachets (9424B) Zollinger-Ellison syndrome Treatment criteria: Must be treated by a gastroenterologist or in consultation with a gastroenterologist Low dose proton pump inhibitors are appropriate step-down therapy from standard dose proton pump inhibitors A low dose proton pump inhibitor includes: lansoprazole 15mg, omeprazole 10mg, pantoprazole 20mg and rabeprazole 10mg steppingup therapy No increase in the maximum quantity or number of repeats may be authorised.

7 Name, Restriction, Pantoprazole 40mg enteric tablet, 30 (8008L) Max. Pantoprazole 40mg enteric coated granules, 30 sachets (9424B) Gastro-oesophageal reflux disease Clinical criteria: The treatment must be maintenance therapy for erosive reflux oesophagitis AND The condition must have been previously diagnosed by endoscopy Low dose proton pump inhibitors are appropriate step-down therapy from standard dose proton pump inhibitors A low dose proton pump inhibitor includes: lansoprazole 15mg, omeprazole 10mg, pantoprazole 20mg and rabeprazole 10mg No increase in the maximum quantity or number of repeats may be authorised.

8 Name, Restriction, Pantoprazole 40mg enteric tablet, 30 (New) 1 1 Pantoprazole 40mg enteric coated granules, 30 sachets (New) 1 1 Gastro-oesophageal reflux disease Clinical criteria: The treatment must be for initial treatment of symptomatic gastro-oesophageal reflux disease OR The treatment must be for the short-term maintenance treatment of gastrooesophageal reflux disease Low dose proton pump inhibitors are appropriate step-down therapy from standard dose proton pump inhibitors A low dose proton pump inhibitor includes: lansoprazole 15mg, omeprazole 10mg, pantoprazole 20mg and rabeprazole 10mg stepping-up therapy No increase in the maximum quantity or number of repeats may be authorised.

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty. Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole

More information

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment

More information

High use of maintenance therapy after triple therapy regimes in Ireland

High use of maintenance therapy after triple therapy regimes in Ireland High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity

More information

European Medicines Agency decision

European Medicines Agency decision EMA/124630/2012 European Medicines Agency decision P/0055/2012 of 26 March 2012 on the acceptance of a modification of an agreed paediatric investigation plan for rabeprazole (sodium) (Pariet and associated

More information

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia

More information

Public Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium

Public Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium Public Assessment Report Scientific discussion Rabeprazolnatrium Torrent Pharma 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium DK/H/1819/001-002/DC This module reflects the scientific discussion

More information

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf

More information

Proton Pump Inhibitors. Description

Proton Pump Inhibitors. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors

More information

PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW

PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related

More information

Proton Pump Inhibitors

Proton Pump Inhibitors Market DC Proton Pump Inhibitors Override(s) Prior Authorization Quantity Limit** Approval Duration Preferred PPI: No Prior Authorization required Preferred PPI quantity override: Lifetime Non-Preferred

More information

Proton Pump Inhibitor De-prescribing Guidance

Proton Pump Inhibitor De-prescribing Guidance Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page

More information

Measuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations

Measuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,

More information

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors

More information

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers

More information

Setting The setting was primary care. The economic analysis was conducted in Glasgow, UK.

Setting The setting was primary care. The economic analysis was conducted in Glasgow, UK. Helicobacter pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting Forrest E H, MacKenzie J F, Stuart R C, Morris A J Record Status This is a critical abstract

More information

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Proton Pump Inhibitors Drug Class Prior Authorization Protocol Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS GASTRO-ENTEROLOGY DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS GASTRO-ENTEROLOGY DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, October 2007 Doc. Ref. EMEA/527934/2007 ASSESSMENT OF THE PAEDIATRIC NEEDS GASTRO-ENTEROLOGY DISCLAIMER The Paediatric Working Party

More information

Patient advice regarding long term use of Proton Pump Inhibitors (PPIs)

Patient advice regarding long term use of Proton Pump Inhibitors (PPIs) Patient advice regarding long term use of Proton Pump Inhibitors (PPIs) Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. PROTON PUMP INHIBITORS, NON-PREFERRED FORMS: ACIPHEX (rabeprazole sodium EC) oral tablet ACIPHEX SPRINKLE (rabeprazole sodium DR) oral capsule ESOMEPRAZOLE STRONTIUM (esomeprazole strontium DR) oral capsule

More information

Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada

Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and

More information

Gastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D

Gastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:

More information

Package leaflet: Information for the patient. Rabeprazole 20 mg Gastro-resistant Tablets. (rabeprazole sodium)

Package leaflet: Information for the patient. Rabeprazole 20 mg Gastro-resistant Tablets. (rabeprazole sodium) Package leaflet: Information for the patient Rabeprazole 10 mg Gastro-resistant Tablets Rabeprazole 20 mg Gastro-resistant Tablets (rabeprazole sodium) Read all of this leaflet carefully before you start

More information

Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors

Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,

More information

Study population The study population comprised hypothetical patients with gastric and duodenal ulcer.

Study population The study population comprised hypothetical patients with gastric and duodenal ulcer. Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical

More information

EU RISK MANAGEMENT PLAN (EU RMP)

EU RISK MANAGEMENT PLAN (EU RMP) EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and

More information

Package leaflet: Information for the user. PARIET 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium

Package leaflet: Information for the user. PARIET 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium Package leaflet: Information for the user PARIET 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium Read all of this leaflet carefully before you start taking this medicine because it contains

More information

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials. Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs

More information

A. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.

A. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer. Pharmacology - Problem Drill 21: Drugs Used To Treat GI Disorders No. 1 of 10 1. Endogenous secretagogues for stomach acid include: #01 (A) Histamine (B) Gastrin (C) PGE1 (D) A and B (E) A, B and C Histamine

More information

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both

More information

This PDF is available for free download from a site hosted by Medknow Publications

This PDF is available for free download from a site hosted by Medknow Publications Research Paper www.ijpsonline.com Inter-Individual Variation in Pharmacokinetics of Proton Pump Inhibitors in Healthy Indian Males SHUBHA RANI AND HARISH PADH* B. V. Patel Pharmaceutical Education and

More information

Source of effectiveness data The effectiveness data were derived from a review and synthesis of completed studies.

Source of effectiveness data The effectiveness data were derived from a review and synthesis of completed studies. Economic evaluation of maintenance therapies for reflux esophagitis: comparison between step-up therapies and step-down therapies Sugano K, Kobayashi M Record Status This is a critical abstract of an economic

More information

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet

More information

OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)

OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I) ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE

More information

Difference between omeprazole and omeprazole delayed release

Difference between omeprazole and omeprazole delayed release Cari untuk: Cari Cari Difference between omeprazole and omeprazole delayed release 7-2-2018 Easy to read patient leaflet for Omeprazole Delayed-Release Capsules. Includes indications, proper use, special

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.209 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

Policy Evaluation: Proton Pump Inhibitors (PPIs)

Policy Evaluation: Proton Pump Inhibitors (PPIs) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Setting The setting was secondary care. The economic study was carried out in Hong Kong, China.

Setting The setting was secondary care. The economic study was carried out in Hong Kong, China. Cost-effectiveness of Helicobacter pylori "test and treat" for patients with typical reflux symptoms in a population with a high prevalence of H. pylori infection: a Markov model analysis You J H, Wong

More information

Peptic ulcer disease Disorders of the esophagus

Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth

More information

Clinical guideline Published: 3 September 2014 nice.org.uk/guidance/cg184

Clinical guideline Published: 3 September 2014 nice.org.uk/guidance/cg184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Clinical guideline Published: 3 September 2014 nice.org.uk/guidance/cg184 NICE 2014. All rights reserved. Last modified

More information

AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan

AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan AstraZeneca K.K. Daiichi Sankyo Co., Ltd. AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan Osaka and Tokyo, Japan, April 18,

More information

Package leaflet: Information for the user. Ulcerbrex 20 mg gastro-resistant tablets Rabeprazole sodium

Package leaflet: Information for the user. Ulcerbrex 20 mg gastro-resistant tablets Rabeprazole sodium Package leaflet: Information for the user Ulcerbrex 20 mg gastro-resistant tablets Rabeprazole sodium Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

All Indiana Medicaid Prescribers and Pharmacy Providers

All Indiana Medicaid Prescribers and Pharmacy Providers P R O V I D E R B U L L E T I N BT200148 NOVEMBER 28, 2001 To: All Indiana Medicaid Prescribers and Pharmacy Providers Subject: Note: The information in this bulletin regarding prior authorization payment

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ULCERBREX 10 mg mg gastro-resistant tablets Rabeprazole sodium

PACKAGE LEAFLET: INFORMATION FOR THE USER. ULCERBREX 10 mg mg gastro-resistant tablets Rabeprazole sodium PACKAGE LEAFLET: INFORMATION FOR THE USER ULCERBREX 10 mg mg gastro-resistant tablets Rabeprazole sodium Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées

More information

H o w d o e a c t. y o u r a c i

H o w d o e a c t. y o u r a c i H o w d o e a c t p a n t o p r a b r e a k d y o u r a c i Pantoprazole Sodium is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic,

More information

Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn

Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn University of Groningen Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn IMPORTANT NOTE: You are advised to consult

More information

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this

More information

Package leaflet: Information for the user. Omeprazol STADA 20 mg gastro-resistant tablets Omeprazole

Package leaflet: Information for the user. Omeprazol STADA 20 mg gastro-resistant tablets Omeprazole Package leaflet: Information for the user Omeprazol STADA 20 mg gastro-resistant tablets Omeprazole Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Committee Approval Date: October 14, 2014 Next Review Date: October 2015

Committee Approval Date: October 14, 2014 Next Review Date: October 2015 Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next

More information

Management of dyspepsia and of Helicobacter pylori infection

Management of dyspepsia and of Helicobacter pylori infection Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia

More information

Internal Clinical Guidelines Team

Internal Clinical Guidelines Team Internal Clinical Guidelines Team Full Guideline Dyspepsia and gastrooesophageal reflux disease: investigation and management of dyspepsia, symptoms suggestive of gastro-oesophageal reflux disease, or

More information

Some H2 Antihistaminics And Ppi-S Products Authorized In Albania And Their Availability For Pediatric Groups

Some H2 Antihistaminics And Ppi-S Products Authorized In Albania And Their Availability For Pediatric Groups Some H2 Antihistaminics And Ppi-S Products Authorized In Albania And Their Availability For Pediatric Groups Briseida Dosti, Msc. Ledjan Malaj, Prof. Medicine University of Tirana, Faculty of Pharmacy,

More information

Concise guide to management of reflux disease in primary care

Concise guide to management of reflux disease in primary care Drug review GORD Concise guide to management of reflux disease in primary care Kumar Kanti Basu BSc, FRCP Reflux is a common disorder often aggravated by lifestyle and other medications. Our Drug review

More information

Setting The setting was community. The economic study was carried out in the USA.

Setting The setting was community. The economic study was carried out in the USA. Costs of managing Helicobacter pylori-infected ulcer patients after initial therapy Griffiths R I, Rabeneck L, Guzman G, Cromwell D M, Strauss M J, Robinson J W, Winston B, Li T, Graham D Y Record Status

More information

Controloc 40 mg is used for:

Controloc 40 mg is used for: Name Controloc 40 mg gastro-resistant tablets Pantoprazole Before you start taking this medicine Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need

More information

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient V020 Package leaflet: Information for the patient Rabeprazole Sodium Actavis 10 mg Gastro-resistant Tablets Rabeprazole Sodium Actavis 20 mg Gastro-resistant Tablets Rabeprazole sodium Read all of this

More information

1.1 Product name: RABESTA-10 (Rabeprazole sodium Tablets 10 mg) 1.2 Strength: Each enteric coated tablet contains: Rabeprazole sodium...

1.1 Product name: RABESTA-10 (Rabeprazole sodium Tablets 10 mg) 1.2 Strength: Each enteric coated tablet contains: Rabeprazole sodium... SUMMARY OF PRODUCT CHARACTERISTICS (PRODUCT DATA SHEET) 1. Name of the medicinal Product 1.1 Product name: RABESTA-10 (Rabeprazole sodium Tablets 10 mg) 1.2 Strength: Each enteric coated tablet contains:

More information

Zantac for stomach ulcers

Zantac for stomach ulcers P ford residence southampton, ny Zantac for stomach ulcers Information on the drug ranitidine (Zantac) used in and duodenal ulcers, heartburn, esophagitis, and Zollinger Ellison Syndrome. Side. But with

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 September 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 September 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 September 2011 GAVISCON PEPPERMINT, chewable tablet B/20 (CIP code: 367 909-6) GAVISCON, oral suspension 250 ml

More information

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)

PPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI) Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations

More information

LOSEC MUPS 10 mg, 20 mg and 40 mg Tablets ASTRAZENECA

LOSEC MUPS 10 mg, 20 mg and 40 mg Tablets ASTRAZENECA 10-14 LOSEC MUPS 10 mg, 20 mg and 40 mg Tablets ASTRAZENECA omeprazole Tablets Composition Each tablet contains: Omeprazole magnesium 10.3 mg, 20.6 mg and 41.3 mg (corresponding to omeprazole 10 mg, 20

More information

Chemmart Rabeprazole Tablets Contains the active ingredient rabeprazole (as rabeprazole sodium)

Chemmart Rabeprazole Tablets Contains the active ingredient rabeprazole (as rabeprazole sodium) Chemmart Rabeprazole Tablets Contains the active ingredient rabeprazole (as rabeprazole sodium) Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet

More information

NOXICID CAPS Esomeprazole (as magnesium) PRODUCT INFORMATION

NOXICID CAPS Esomeprazole (as magnesium) PRODUCT INFORMATION Noxicid Caps Product Information 1 NOXICID CAPS Esomeprazole (as magnesium) PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient : esomeprazole magnesium Chemical name : di-(s)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1hbenzimidazole

More information

Rabeprazole Clonmel 10mg Gastro-resistant Tablets Rabeprazole Clonmel 20mg Gastro-resistant Tablets

Rabeprazole Clonmel 10mg Gastro-resistant Tablets Rabeprazole Clonmel 20mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER Rabeprazole Clonmel 10mg Gastro-resistant Tablets Rabeprazole Clonmel 20mg Gastro-resistant Tablets Rabeprazole sodium Read all of this leaflet carefully before

More information

Prevpac Pylera Omeclamox-Pak

Prevpac Pylera Omeclamox-Pak Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,

More information

Losamel 20mg Gastro-resistant Tablets

Losamel 20mg Gastro-resistant Tablets Package leaflet: Information for the user Losamel 20mg Gastro-resistant Tablets Omeprazole Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET NEW ZEALAND DATA SHEET PANZOP RELIEF Pantoprazole 20 mg & 40 mg Gastro-Resistant tablets Presentation Panzop Relief 20 mg tablets are dark yellow, oval, biconvex, enteric coated tablets, with PS2 printed

More information

Management of Dyspepsia

Management of Dyspepsia MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively

More information

Package leaflet: Information for the user. Nolpaza 40 mg gastro-resistant tablets. Pantoprazole

Package leaflet: Information for the user. Nolpaza 40 mg gastro-resistant tablets. Pantoprazole Package leaflet: Information for the user 40 mg gastro-resistant tablets Pantoprazole Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Patient s awareness and education with respect to the safe and appropriate use of medicines with special attention to OTC medicines Regulatory view

Patient s awareness and education with respect to the safe and appropriate use of medicines with special attention to OTC medicines Regulatory view s awareness and education with respect to the safe and appropriate use of medicines with special attention to OTC medicines Regulatory view EDQM Expert workshop: OTC medicines: The role of good classification

More information

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,

More information

Package leaflet: Information for the patient <invented name> 20 mg Gastro-Resistant Tablets <invented name> 40 mg Gastro-Resistant Tablets

Package leaflet: Information for the patient <invented name> 20 mg Gastro-Resistant Tablets <invented name> 40 mg Gastro-Resistant Tablets Package leaflet: Information for the patient 20 mg Gastro-Resistant Tablets 40 mg Gastro-Resistant Tablets Esomeprazole Read all of this leaflet carefully before you start

More information

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011 KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology

More information

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES 1 Member State EU/EEA Austria Denmark Finland France Germany

More information

New Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders

New Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders ...SYMPOSIUM PROCEEDINGS... New Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders Based on a presentation by Duane D. Webb, MD, FACG Presentation Summary Gastroesophageal reflux

More information

Applicant Invented name Strength Pharmaceutical Form Route of administration HEXAL AG Industriestraße 25 D Holzkirchen.

Applicant Invented name Strength Pharmaceutical Form Route of administration HEXAL AG Industriestraße 25 D Holzkirchen. ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Austria - Marketing

More information

Class Update: Proton Pump Inhibitors and Histamine 2 Receptor Antagonists

Class Update: Proton Pump Inhibitors and Histamine 2 Receptor Antagonists Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS Rabeprazole, UK/H/1519/01-02, 28.07.17 1. NAME OF THE MEDICINAL PRODUCT Rabeprazole sodium 10 mg Gastro-resistant Tablets Rabeprazole sodium 20 mg Gastro-resistant Tablets

More information

Treatments for Barrett s Oesophagus

Treatments for Barrett s Oesophagus Is it really just Heartburn? Treatments for Barrett s Oesophagus Introduction This leaflet describes the various ways in which Barrett s Oesophagus is treated. It has been produced in association with

More information

How Rabeprazole Sandoz works

How Rabeprazole Sandoz works Rabeprazole (as sodium) enteric coated tablets Consumer Medicine Information WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Rabeprazole Sandoz. It does not contain all the available

More information

Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W

Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that

More information

1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication

1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication Investigation 10mg 1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication Blister packs of 14 Solid dose form for oral administration. It

More information

Drug Class Review on Proton Pump Inhibitors

Drug Class Review on Proton Pump Inhibitors Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May

More information

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rabeprazole sodium 20 mg gastro-resistant tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablet contains 20

More information

Prakruti Life Science

Prakruti Life Science Prakruti Life Science is a well established and recognized name in pharmaceutical industry in India. Prakruti Life Science Pvt Ltd is located at coastal belt of Karnataka. The Manufacturing Unit is situation

More information

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35. An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology

More information

QUICK QUERIES. Topical Questions, Sound Answers

QUICK QUERIES. Topical Questions, Sound Answers QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University

More information

Management of dyspepsia in adults in primary care

Management of dyspepsia in adults in primary care Dyspepsia Management of dyspepsia in adults in primary care June 2005. The recommendations on referral for endoscopy in this NICE guideline have been amended in line with the recommendation in the NICE

More information

International Journal of Research in Pharmacology & Pharmacotherapeutics

International Journal of Research in Pharmacology & Pharmacotherapeutics International Journal of Research in Pharmacology & Pharmacotherapeutics ISSN Print: 2278-2648 IJRPP Vol.6 Issue 3 July - Sep - 2017 ISSN Online: 2278-2656 Journal Home page: Research article Open Access

More information

Drug Class Review on Proton Pump Inhibitors

Drug Class Review on Proton Pump Inhibitors Drug Class Review on Proton Pump Inhibitors Evidence Tables July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May 2005

More information

This leaflet answers some of the common questions people ask about Pharmacor Omeprazole.

This leaflet answers some of the common questions people ask about Pharmacor Omeprazole. PHARMACOR OMEPRAZOLE CAPSULES Omeprazole Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about Pharmacor Omeprazole. It does not contain

More information

Drug Class Review Proton Pump Inhibitors

Drug Class Review Proton Pump Inhibitors Drug Class Review Proton Pump Inhibitors Evidence Tables April 2009 Update 4: May 2006 Update 3: May 2005 Update 2: April 2004 Update 1: April 2003 Original Report: November 2002 The literature on this

More information

ALL WALES PROTON PUMP INHIBITOR AND DYSPEPSIA RESOURCE PACK MATERIAL TO SUPPORT APPROPRIATE PRESCRIBING OF PROTON PUMP INHIBITORS ACROSS WALES

ALL WALES PROTON PUMP INHIBITOR AND DYSPEPSIA RESOURCE PACK MATERIAL TO SUPPORT APPROPRIATE PRESCRIBING OF PROTON PUMP INHIBITORS ACROSS WALES ALL WALES PROTON PUMP INHIBITOR AND DYSPEPSIA RESOURCE PACK MATERIAL TO SUPPORT APPROPRIATE PRESCRIBING OF PROTON PUMP INHIBITORS ACROSS WALES April 2013 This document has been prepared by a multiprofessional

More information

PATIENT INFORMATION LEAFLET PEPLOC RANGE

PATIENT INFORMATION LEAFLET PEPLOC RANGE Scheduling Status: S4 Proprietary name, Strength and Pharmaceutical Form: Peploc 20 mg tablets Peploc 40 mg tablets Read all of this leaflet carefully before using PEPLOC 20 mg or 40 mg Keep this leaflet.

More information

Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial

Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial Alimentary Pharmacology & Therapeutics Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial E. BJÖRNSSON, H. ABRAHAMSSON, M. SIMRÉN, N. MATTSSON,

More information